openPR Logo
Press release

Anti-Epilepsy Drugs Market 2018 – Key Vendors are Pfizer, Inc., Johnson & Johnson, UCB Pharma Ltd., Abbott, Etc – MarketResearchFuture.com

06-27-2018 09:18 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: Market Research Future

Anti-Epilepsy Drugs Market

Anti-Epilepsy Drugs Market

Market Research Future published a research report on Global Anti-Epilepsy Drugs Market and provide country level analysis of the market for segments by type of seizures (seizures (generalized seizures and partial-onset seizures) and by generation (first, second and third)

Anti-Epilepsy Drugs Market Scenario:

Market Research Future firm published study report “Global Anti Epilepsy Drugs Market - Forecast to 2022” report provide country level analysis of the market with respect to the current market size and future prospective and provide country level analysis of the market for segments by type of seizures (seizures (generalized seizures and partial-onset seizures) and by generation (first, second and third).

Epilepsy is a group of neurological disorders characterized by seizures manifesting as brief, involuntary episodes of vigorous shaking of a part or complete body. The patient may experience loss or disturbance of consciousness and movements along with sensory or psychiatric disturbances. About 24 million people around the globe suffer from epilepsy with the global epilepsy drugs market reaching USD 3.7 billion in 2015. It is estimated that this market has the potential to reach USD 4.8 billion in 2022 representing a CAGR of 3.79%.

Get Sample PDF Illustration @ https://www.marketresearchfuture.com/sample_request/2345 .

Key Players for Global Anti-Epilepsy Drugs Market

Pfizer, Inc., Johnson & Johnson, UCB Pharma Ltd., Abbott Laboratories, GlaxoSmithKline plc, Novartis International AG, Sanofi S.A., Shire Pharmaceuticals Limited and Cephalon Inc.

The Major Driving Factor for the Growth are:

Development of better tolerated third generation drugs
Increasing screening of patients, penetration and availability of drugs
Growth of geriatrics as they are affected more by epilepsy
Comparative lower competition in anti-epilepsy drugs as most drugs act by similar action. Thus, advent of a novel drug will make it a blockbuster with easy uptake and less marketing cost
Support for drug research and awareness created by social and government bodies

The constraints of the market are:

Loss of patents for a number of anti-epilepsy drugs such as Neurontin (2003) and Lyrica (scheduled in 2018)
Unknown origins and mechanism of action of epilepsy and concurrent lack of new novel acting drugs
Historical dominance of Gamma Aminobutyric Acid modulators and ion channel blockers, even though a sizeable segment of patients respond very poorly or none at all to these drugs
Associated side-effects, such as depression and suicide behavior, dizziness, fatigue, weight gain etc. of major class of drugs
High cost of clinical trials and extensive post market surveillance as it is difficult to separate cause and effect of drugs in epilepsy
Social stigma associated with epilepsy especially in the developing world

Segments for Global Anti-Epilepsy Drugs Market

Global Anti-Epilepsy Drugs market has been segmented on the basis of types of seizures, generation, and region.

Regional Analysis for Global Anti-Epilepsy Drugs Market

Globally, North America is the largest market for anti-epilepsy drugs. Europe is the second-largest market for anti-epilepsy drugs. The developing region especially Asia Pacific is accounting for major newer cases due to greater screening and better health care facilities distribution. However the developing regions market particularly Asia Pacific will be the fastest growing and is likely to be the key to the future.

Get Prime Discount on Report @ https://www.marketresearchfuture.com/check-discount/2345 .

Some Brief Table of Contents of Report

Chapter 1. Report Prologue

Chapter 2. Market Introduction

2.1 Definition

2.2 Scope Of The Study

2.2.1 Research Objective

2.2.2 Assumptions

2.2.3 Limitations

Chapter 3. Research Methodology

3.1 Introduction

3.2 Primary Research

3.3 Secondary Research

3.4 Market Size Estimation

Chapter 4. Market Dynamics

4.1 Drivers

4.2 Restrains

4.3 Opportunities

4.4 Challenges

4.5 Macroeconomic Indicators

4.6 Technology Trends & Assessment

Chapter 5. Market Factor Analysis

5.1 Porters Five Forces Analysis

5.1.1 Bargaining Power Of Suppliers

TOC Continued…

List Of Tables

TABLE 1 GLOBAL ANTI-EPILEPSY DRUGS MARKET, 2013-2022 (USD MILLION)

TABLE 2 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY TYPES OF SEIZURES, 2013-2022 (USD MILLION)

TABLE 3 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY GENERATION, 2013-2022 (USD MILLION)

TABLE 4 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY REGION, 2013-2022 (USD MILLION)

List Of Figures

FIGURE 1 RESEARCH PROCESS

FIGURE 2 PORTERS FIVE FORCES MODEL

FIGURE 3 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY TYPES OF SEIZURES

FIGURE 4 GLOBAL ANTI-EPILEPSY DRUGS MARKET, BY GENERATION

Continued…

Do You Have Specific Requirement? Ask To Our Experts@ https://www.marketresearchfuture.com/enquiry/2345 .

About Market Research Future:

At Market Research Future (MRFR), we enable our customers to unravel the complexity of various industries through our Cooked Research Report (CRR), Half-Cooked Research Reports (HCRR), Statistical Report, Continuous-Feed Research (CFR), and Market Research & Consulting Services.

Contact Us:

Market Research Future

Hadapsar, Pune – 411028

Maharashtra, India

Phone: +1 646 845 9312

Email: sales@marketresearchfuture.com

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Anti-Epilepsy Drugs Market 2018 – Key Vendors are Pfizer, Inc., Johnson & Johnson, UCB Pharma Ltd., Abbott, Etc – MarketResearchFuture.com here

News-ID: 1099394 • Views:

More Releases from Market Research Future

9-Decanoic Acid Methyl Ester Market Poised for Strong 6.59% CAGR Growth Through 2035
9-Decanoic Acid Methyl Ester Market Poised for Strong 6.59% CAGR Growth Through …
The 9-decanoic acid methyl ester market is a growing sector driven by the increasing demand for bio-based and sustainable chemical products across various industries. With its unique properties, it finds application in flavors and fragrances, pharmaceuticals, personal care, and as a chemical intermediate. The market is projected to expand significantly in the coming years. Market Overview and Size The global 9-decanoic acid methyl ester market was valued at USD 230.0 million in
Washable Marker Market Poised for 3.54% CAGR Growth During 2024-2032
Washable Marker Market Poised for 3.54% CAGR Growth During 2024-2032
The washable marker market is a dynamic and growing segment within the broader stationery and art supplies industry. Driven by a blend of consumer demands for safety, convenience, and sustainability, the market is experiencing consistent expansion, particularly within the education and home-use sectors. While faced with some challenges, the industry's future looks promising, propelled by product innovation and evolving consumer trends. Get Sample @ https://www.marketresearchfuture.com/sample_request/41217 Market Size and Growth The global washable
Phone Car Mounts Market to Reach USD 7.37 Billion by 2034, Growing at 6.47% CAGR
Phone Car Mounts Market to Reach USD 7.37 Billion by 2034, Growing at 6.47% CAGR
The phone car mounts market, a critical sub-segment of the broader automotive accessories industry, is experiencing robust growth driven by a convergence of technological advancements, evolving consumer behavior, and increasingly stringent road safety regulations. As smartphones become indispensable for navigation, communication, and in-car entertainment, the demand for secure and convenient hands-free solutions continues to escalate. The global phone car mounts market was valued at USD 3.93 billion in 2024 and
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR by 2032
Intravenous (IV) Solution Market Set to Grow to USD 26.60 Billion at 7.70% CAGR …
Market Overview: The Intravenous (IV) Solution Market is estimated to be valued at USD 13.9 billion in 2023 and is projected to reach USD 26.60 billion by 2032, expanding at a compound annual growth rate (CAGR) of 7.70% from 2024 to 2031. The market growth is attributed to the rising prevalence of chronic diseases, growing hospitalization rates, and increasing surgical procedures that require IV fluid administration. Intravenous solutions are critical

All 5 Releases


More Releases for Epilepsy

Portable Epilepsy Monitoring Market in 2025
InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Global Portable Epilepsy Monitoring Market- (By Product Type (Device Type (Chest Sensor, Watch Sensor, Monitors, Cameras, Mattresses and Pillows, and Others) and Service), By End User (Hospitals, Ambulatory Surgery Centres & Clinics, Neurology Centres, and Home Care Settings)), Trends, Industry Competition Analysis, Revenue and Forecast To 2031." According to the latest research by InsightAce Analytic, the Global
Top 10 Epilepsy Companies Analysis (2024)
Epilepsy also known as seizure disorder, is a chronic noncommunicable disease that affects brain. Epilepsy affects people of all races, ethnic backgrounds, genders, and ages. Get More Details with Sample PDF Copy @ https://www.theinsightpartners.com/sample/TIPRE00016405/?utm_source=OpenPR&utm_medium=10129 Major Companies operating in the Epilepsy Market are: • Idexx Laboratories Inc. • PBD Biotech Ltd • Thermo Fisher Scientific Inc. • Innovative Diagnostics SAS • Neogen Corp • Enfer Labs • bioMerieux SA • Ring Biotechnology Co Ltd • Bionote Inc. • Shenzhen Bioeasy Biotechnology Co Ltd. Contact Us: If you have any queries about this report or if
Epilepsy Market: Trends, Opportunities, and Challenges
Epilepsy is a neurological disorder characterized by recurrent seizures, which are caused by abnormal electrical activity in the brain. This condition affects millions of people globally, making it one of the most common neurological disorders. As the global burden of epilepsy increases, the demand for effective treatments and solutions continues to grow. The epilepsy market is evolving rapidly, with advancements in medication, diagnostics, and therapeutic technologies. This guest post aims
Epilepsy Device Market: for Epilepsy Devices Poised to Exceed $1 Billion by 2031 …
The global epilepsy devices market isx experiencing a remarkable surge, poised to exceed a valuation of $1.1 billion by 2031, as revealed by the latest market analysis. According to the report released by Allied Market Research, the market was valued at $675.23 million in 2021 and is projected to grow at a CAGR of 5.1% from 2022 to 2031. 𝐑𝐞𝐪𝐮𝐞𝐬𝐭 𝐅𝐨𝐫 𝐒𝐚𝐦𝐩𝐥𝐞 𝐂𝐨𝐩𝐲: https://www.alliedmarketresearch.com/request-sample/A14821 Epilepsy devices play
Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market - Breaking the Sei …
Newark, New Castle, USA: The "Epilepsy with Myoclonic-Atonic Seizures Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors Epilepsy with Myoclonic - Atonic Seizures Therapeutics Market: https://www.growthplusreports.com/report/epilepsy-with-myoclonic-atonic-seizures-therapeutics-market/8029 This
Rising Instances of Pediatric Epilepsy to Pave Novel Growth Avenues in Epilepsy …
Owing to large scale prevalence of epilepsy cases, inclusive of pediatric epilepsy, the market for epilepsy drugs is likely to remain agile in the coming years. Prevalent amongst both male and female demographics alike, epilepsy is a critical condition that affects the brain both partially as well as in whole. Lucrative reimbursement policies, coupled with growing patient awareness about novel therapeutics are likely to reflect favorably on the growth curve